Like rival Fitch, Moody's cited "debt-financed share repurchases," saying they're not the norm for fiscally conservative Merck and could trigger a one-notch rating downgrade. Moody's also noted "pressures facing Merck's business, including a worse-than-expected impact from generic competition and moderating growth" for its popular pills for it Type 2 diabetes.